Please use this identifier to cite or link to this item:
|Title:||A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial||Authors:||Roger, Simon D ;Brigandi, R.A.;Johnson, B.;Oei, C.;Westerman, M.;Olbina, G.;de Zoysa, J.;Sahay, M.;Cross, N.;McMahon, L.;Guptha, V.;Smolyarchuk, E.A.;Singh, N.;Russ, S.F.;Kumar, S.||Affliation:||Central Coast Local Health District
|Issue Date:||Jun-2016||Source:||67(6):861-71||Journal title:||American Journal of Kidney Diseases||Department:||Renal||Abstract:||BACKGROUND: Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin (EPO). Hypoxia-inducible factor-prolyl hydroxylase inhibitors (PHIs) stimulate endogenous EPO synthesis and induce effective erythropoiesis by non-EPO effects. GSK1278863 is an orally administered small-molecule PHI. STUDY DESIGN: Multicenter, single-blind, randomized, placebo-controlled, parallel-group study. SETTING & PARTICIPANTS: Anemic non-dialysis-dependent patients with CKD stages 3-5 (CKD-3/4/5 group; n=70) and anemic hemodialysis patients with CKD stage 5D (CKD-5D group; n=37). INTERVENTIONS: Patients with CKD-3/4/5 received placebo or GSK1278863 (10, 25, 50, or 100mg), and patients with CKD-5D received placebo or GSK1278863 (10 or 25mg) once daily for 28 days. OUTCOMES & MEASUREMENTS: Primary pharmacokinetic and pharmacodynamic (increase and response rates in achieving the target hemoglobin [Hb] concentration, plasma EPO concentrations, reticulocyte count, and others]) and safety and tolerability end points were obtained. RESULTS: Both CKD-3/4/5 and CKD-5D populations showed a dose-dependent increase in EPO concentrations and consequent increases in reticulocytes and Hb levels. Percentages of GSK1278863 participants with an Hb level increase > 1.0g/dL (CKD-3/4/5) and >0.5g/dL (CKD-5D) were 63% to 91% and 71% to 89%, respectively. Per-protocol-defined criteria, high rate of increase in Hb level, or high absolute Hb value was the main cause for withdrawal (CKD-3/4/5, 30%; CKD-5D, 22%). A dose-dependent decrease in hepcidin levels and increase in total and unsaturated iron binding were observed in all GSK1278863-treated patients. LIMITATIONS: Sparse pharmacokinetic sampling may have limited covariate characterization. EPO concentrations at the last pharmacodynamic sample (5-6 hours) postdose may not represent peak concentrations, which occurred 8 to 10 hours postdose in previous studies. Patients were not stratified by diabetes status, potentially confounding vascular endothelial growth factor and glucose analyses. CONCLUSIONS: GSK1278863 induced an effective EPO response and stimulated non-EPO mechanisms for erythropoiesis in anemic non-dialysis-dependent and dialysis-dependent patients with CKD.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1385||DOI:||10.1053/j.ajkd.2015.11.021||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/26827289||ISSN:||0272-6386||Publicaton type:||Journal Article||Keywords:||Kidney Disease
|Study or Trial:||Randomized Controlled Clinical Trial/Controlled Clinical Trial|
|Appears in Collections:||Renal Medicine|
Show full item record
checked on Feb 3, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.